ImmuCell (NASDAQ:ICCC) Releases Quarterly Earnings Results, Beats Estimates By $0.16 EPS

ImmuCell (NASDAQ:ICCC) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16, FiscalAI reports. The firm had revenue of $10.36 million during the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a negative net margin of 3.76% and a negative return on equity of 3.60%.

ImmuCell Price Performance

Shares of NASDAQ:ICCC traded down $0.10 on Thursday, reaching $8.26. The company’s stock had a trading volume of 25,190 shares, compared to its average volume of 22,140. The company has a 50-day simple moving average of $7.20 and a 200 day simple moving average of $6.44. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.93 and a current ratio of 4.26. The company has a market cap of $74.75 million, a P/E ratio of -75.08 and a beta of 0.50. ImmuCell has a 52-week low of $4.52 and a 52-week high of $9.08.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC raised its stake in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,852 shares of the biotechnology company’s stock after purchasing an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 13.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell presently has an average rating of “Sell”.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.